- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.08. | Stealth resubmits rare disease drug to FDA | ||
| 18.08. | Kennedy's mRNA cuts could set US science back, experts warn | ||
| 18.08. | Reunion's psychedelic drug headed to late-stage testing | ||
| 18.08. | Novo's Wegovy becomes first GLP-1 drug approved for MASH | ||
| 18.08. | The unexpected medication that could revolutionize the treatment of Alzheimer's disease | ||
| 18.08. | Navigating the oncology patent cliff: Strategic imperatives for big pharma | ||
| 15.08. | HHS revives defunct task force on childhood vaccine safety | ||
| 15.08. | Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial | ||
| 15.08. | Merck KGaA ventures into new territory in the US | ||
| 14.08. | Lilly says it will raise drug prices in Europe, responding to Trump threats | ||
| 14.08. | Sarepta sells Arrowhead shares as partnership, debt payments loom | ||
| 14.08. | Vedanta, PureTech's microbiome startup, to cut staff after study setback | ||
| 13.08. | Vor says drug licensed from RemeGen succeeded in Sjögren's study | ||
| 13.08. | AbbVie to build API plant in Illinois as it steps up US production | ||
| 12.08. | Insmed gains US approval of lung disease drug forecast to be blockbuster | ||
| 12.08. | PureTech launches new biotech built around lung disease drug | ||
| 12.08. | Pfizer looks to expand ADC use after positive bladder cancer data | ||
| 12.08. | Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3 | ||
| 12.08. | Expedition, a startup searching for drugs from China, cuts its first deal | ||
| 11.08. | IO Biotech sees path forward for skin cancer vaccine despite study setback | ||
| 11.08. | As gene therapy sales sputter, one biotech aims to defy the odds | ||
| 11.08. | Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease | ||
| 11.08. | Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP | ||
| 08.08. | BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal | ||
| 08.08. | Inside AstraZeneca's long-term strategy in lung cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .